Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis

2.50
Hdl Handle:
http://hdl.handle.net/11287/618029
Title:
Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis
Authors:
Perry, Mandy ( 0000-0003-4303-2718 ) ; McDonald, Timothy J. ( 0000-0003-3559-6660 ) ; Cudmore, Adrian; Ahmad, Tariq
Abstract:
The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is associated with production of antibodies to the therapy. Measuring trough drug and antibody concentrations may direct patient management in future.
Citation:
Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis. 2015. Clinical Laboratory International
Publisher:
Clinical Laboratory International
Journal:
Clinical Laboratory International
Issue Date:
2-Nov-2015
URI:
http://hdl.handle.net/11287/618029
Additional Links:
http://www.cli-online.com/index.php?id=4173
Type:
Journal Article
Language:
en
Appears in Collections:
2015 RD&E publications; Gastroenterology; Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology)

Full metadata record

DC FieldValue Language
dc.contributor.authorPerry, Mandyen
dc.contributor.authorMcDonald, Timothy J.en
dc.contributor.authorCudmore, Adrianen
dc.contributor.authorAhmad, Tariqen
dc.date.accessioned2016-08-08T11:50:02Z-
dc.date.available2016-08-08T11:50:02Z-
dc.date.issued2015-11-02-
dc.identifier.citationMeasuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis. 2015. Clinical Laboratory Internationalen
dc.identifier.urihttp://hdl.handle.net/11287/618029-
dc.description.abstractThe anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is associated with production of antibodies to the therapy. Measuring trough drug and antibody concentrations may direct patient management in future.en
dc.language.isoenen
dc.publisherClinical Laboratory Internationalen
dc.relation.urlhttp://www.cli-online.com/index.php?id=4173en
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleMeasuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitisen
dc.typeJournal Articleen
dc.identifier.journalClinical Laboratory Internationalen
dc.type.versionPublisheden
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.